Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts

Jesus Delgado-Calle, Noriyoshi Kurihara, Emily G. Atkinson, Jessica Nelson, Kazuaki Miyagawa, Carlos Maria Galmarini, G. David Roodman, Teresita Bellido

Research output: Contribution to journalArticle

Abstract

Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission. Thus, identification of new therapeutic agents that simultaneously suppress MM growth and protect bone is an unmet need. Herein, we examined the effects of Aplidin, a novel anti-cancer marine-derived compound, on MM and bone cells. In vitro, Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced osteocyte/osteoblast viability and decreased osteoblast mineralization, effects that were enhanced by Dex and partially prevented by Btz. Further, Aplidin markedly decreased osteoclast precursor numbers and differentiation, and reduced mature osteoclast number and resorption activity. Moreover, Aplidin reduced Dex-induced osteoclast differentiation and further decreased osteoclast number when combined with Btz. Lastly, Aplidin alone, or suboptimal doses of Aplidin combined with Dex or Btz, decreased tumor growth and bone resorption in ex vivo bone organ cultures that reproduce the 3D-organization and the cellular diversity of the MM/bone marrow niche. These results demonstrate that Aplidin has potent anti-myeloma and anti-resorptive properties, and enhances proteasome inhibitors blockade of MM growth and bone destruction.

Original languageEnglish (US)
Pages (from-to)2709-2721
Number of pages13
JournalOncotarget
Volume10
Issue number28
DOIs
StatePublished - Apr 12 2019

Fingerprint

Osteoclasts
Multiple Myeloma
Dexamethasone
Bone Development
Osteoblasts
Bone and Bones
Osteocytes
Proteasome Inhibitors
aplidine
Bone Diseases
Organ Culture Techniques
Bone Resorption
Growth
Neoplasms
Bone Marrow
Apoptosis
Bortezomib

Keywords

  • Myeloma
  • Osteoblasts
  • Osteoclasts
  • Osteocytes
  • Tumor

ASJC Scopus subject areas

  • Oncology

Cite this

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. / Delgado-Calle, Jesus; Kurihara, Noriyoshi; Atkinson, Emily G.; Nelson, Jessica; Miyagawa, Kazuaki; Galmarini, Carlos Maria; Roodman, G. David; Bellido, Teresita.

In: Oncotarget, Vol. 10, No. 28, 12.04.2019, p. 2709-2721.

Research output: Contribution to journalArticle

@article{594473134443410eb18934532b6615ff,
title = "Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts",
abstract = "Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission. Thus, identification of new therapeutic agents that simultaneously suppress MM growth and protect bone is an unmet need. Herein, we examined the effects of Aplidin, a novel anti-cancer marine-derived compound, on MM and bone cells. In vitro, Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced osteocyte/osteoblast viability and decreased osteoblast mineralization, effects that were enhanced by Dex and partially prevented by Btz. Further, Aplidin markedly decreased osteoclast precursor numbers and differentiation, and reduced mature osteoclast number and resorption activity. Moreover, Aplidin reduced Dex-induced osteoclast differentiation and further decreased osteoclast number when combined with Btz. Lastly, Aplidin alone, or suboptimal doses of Aplidin combined with Dex or Btz, decreased tumor growth and bone resorption in ex vivo bone organ cultures that reproduce the 3D-organization and the cellular diversity of the MM/bone marrow niche. These results demonstrate that Aplidin has potent anti-myeloma and anti-resorptive properties, and enhances proteasome inhibitors blockade of MM growth and bone destruction.",
keywords = "Myeloma, Osteoblasts, Osteoclasts, Osteocytes, Tumor",
author = "Jesus Delgado-Calle and Noriyoshi Kurihara and Atkinson, {Emily G.} and Jessica Nelson and Kazuaki Miyagawa and Galmarini, {Carlos Maria} and Roodman, {G. David} and Teresita Bellido",
year = "2019",
month = "4",
day = "12",
doi = "10.18632/oncotarget.26831",
language = "English (US)",
volume = "10",
pages = "2709--2721",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

TY - JOUR

T1 - Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts

AU - Delgado-Calle, Jesus

AU - Kurihara, Noriyoshi

AU - Atkinson, Emily G.

AU - Nelson, Jessica

AU - Miyagawa, Kazuaki

AU - Galmarini, Carlos Maria

AU - Roodman, G. David

AU - Bellido, Teresita

PY - 2019/4/12

Y1 - 2019/4/12

N2 - Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission. Thus, identification of new therapeutic agents that simultaneously suppress MM growth and protect bone is an unmet need. Herein, we examined the effects of Aplidin, a novel anti-cancer marine-derived compound, on MM and bone cells. In vitro, Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced osteocyte/osteoblast viability and decreased osteoblast mineralization, effects that were enhanced by Dex and partially prevented by Btz. Further, Aplidin markedly decreased osteoclast precursor numbers and differentiation, and reduced mature osteoclast number and resorption activity. Moreover, Aplidin reduced Dex-induced osteoclast differentiation and further decreased osteoclast number when combined with Btz. Lastly, Aplidin alone, or suboptimal doses of Aplidin combined with Dex or Btz, decreased tumor growth and bone resorption in ex vivo bone organ cultures that reproduce the 3D-organization and the cellular diversity of the MM/bone marrow niche. These results demonstrate that Aplidin has potent anti-myeloma and anti-resorptive properties, and enhances proteasome inhibitors blockade of MM growth and bone destruction.

AB - Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission. Thus, identification of new therapeutic agents that simultaneously suppress MM growth and protect bone is an unmet need. Herein, we examined the effects of Aplidin, a novel anti-cancer marine-derived compound, on MM and bone cells. In vitro, Aplidin potently inhibited MM cell growth and induced apoptosis, effects that were enhanced by dexamethasone (Dex) and bortezomib (Btz). Aplidin modestly reduced osteocyte/osteoblast viability and decreased osteoblast mineralization, effects that were enhanced by Dex and partially prevented by Btz. Further, Aplidin markedly decreased osteoclast precursor numbers and differentiation, and reduced mature osteoclast number and resorption activity. Moreover, Aplidin reduced Dex-induced osteoclast differentiation and further decreased osteoclast number when combined with Btz. Lastly, Aplidin alone, or suboptimal doses of Aplidin combined with Dex or Btz, decreased tumor growth and bone resorption in ex vivo bone organ cultures that reproduce the 3D-organization and the cellular diversity of the MM/bone marrow niche. These results demonstrate that Aplidin has potent anti-myeloma and anti-resorptive properties, and enhances proteasome inhibitors blockade of MM growth and bone destruction.

KW - Myeloma

KW - Osteoblasts

KW - Osteoclasts

KW - Osteocytes

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=85064987464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064987464&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26831

DO - 10.18632/oncotarget.26831

M3 - Article

AN - SCOPUS:85064987464

VL - 10

SP - 2709

EP - 2721

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -